alexa Bedaquiline A Novel Promising Discovery in Multidrug-Resistant Tuberculosis


Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Bedaquiline A Novel Promising Discovery in Multidrug-Resistant Tuberculosis

 
To read the full article Peer-reviewed Article PDF image

Abstract

After acquired immunodeficiency syndrome (AIDS), tuberculosis (TB) is the leading cause of death worldwide due to a single infectious agent. Recently, drug-resistant strains of mycobacterium tuberculosis reported more horrible version of tuberculosis. There is threatful increase in multidrug resistant tuberculosis (MDR-TB) and extensively drug-resistant TB (XDR-TB) all over the world, so better treatment options are needed to control the global MDR-TB and XDR-TB epidemic. Bedaquiline, a diarylquinoline has a unique mechanism of action i.e. causes inhibition of the proton pump activity of the ATP synthase in mycobacterium tuberculosis and targets the energy metabolism. It acts as a promising new agent in patients with MDR-TB came in market recently. Bedaquiline can be combined with antituberculosis and antiretroviral agents. The drug showed good oral absorption, long terminal half-life and is metabolized mainly by cytochrome 450P3A4. It is recently been approved by U.S. Food and Drug Administration on 28th December, 2012 for treating multi drug resistant TB (MDR-TB) in adults ≥18 years. It seems to be good option for multidrug-resistant tuberculosis patients as it has earlier and sustained antitubercular action, shorten duration of treatment, less chances of resistance and better safety as compared to existing second line drugs. Long term studies are needed to explore its safety.

Keywords

Recommended Journals

Share This Page

Additional Info

Loading
Loading Please wait..
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords